human IgG controls. Table 13 also shows that v870, v871 and v872 bridge a lower percentage of Jurkat T and Raji B cells when compared to the bispecific anti-CD3 anti-CD19 antibody, v873.

TABLE 13

Monovalent anti-CD3 antibody bridging of Jurkat T and Raji B cells

Variant	Description	Jurkat/Raji (%)
Medium		7.0
v870	OAA_anti-CD3 (VH-VL_BiTE)	9.0
v871	OAA_anti-CD3 (VL-VH_BiTE)	15.4
v872	OAA_anti-CD3 (VL-VH_OKT3)	14.0
v873	bispecific CD19-CD3(VH-VL-BiTE)	27.6

TABLE 13-continued

Monovalent anti-CD3 antibody bridging of Jurkat T and Raji B cells

Variant	Description	Jurkat/Raji (%)
Human IgG		6
Medium		7.3

[0542] It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.

SEQUENCE LISTING

The patent application contains a lengthy "Sequence Listing" section. A copy of the "Sequence Listing" is available in electronic form from the USPTO web site (https://seqdata.uspto.gov/?pageRequest=docDetail&DocID=US20210317212A1). An electronic copy of the "Sequence Listing" will also be available from the USPTO upon request and payment of the fee set forth in 37 CFR 1.19(b)(3).

What is claimed is:

1. An isolated polypeptide comprising an Fc variant of a wild-type human IgG Fc, the Fc variant comprising a L234A amino acid substitution, a L235A amino acid substitution, and a D265S amino acid substitution, wherein the amino acid positions are numbered according to the EU index of Kabat.

2. The polypeptide of claim **1**, wherein the polypeptide further comprises at least one antigen-binding domain.

3. The polypeptide of claim **2**, wherein the antigen-binding domain comprises an scFv.

4. The polypeptide of claim **2**, wherein the antigen-binding domain comprises a Fab.

5. The polypeptide of claim **1**, wherein the polypeptide further comprises an scFv and a Fab.

6. The polypeptide of claim **1**, wherein the Fc variant further comprises amino acid substitutions T350V, L351Y, F405A, and Y407V, wherein the amino acid positions are numbered according to the EU index of Kabat.

7. The polypeptide of claim **1**, wherein the Fc variant further comprises amino acid substitutions T350V, T366L, K392L, and T394W, wherein the amino acid positions are numbered according to the EU index of Kabat.

8. The polypeptide of claim **1**, wherein the IgG is an IgG1.

9. The polypeptide of claim **1**, wherein the polypeptide comprises an antibody or an Fc fusion.

10. An antibody comprising the polypeptide of claim **1**.

11. The antibody of claim **10**, wherein the antibody is a monoclonal antibody, a humanized antibody, or a human antibody.

12. The antibody of claim **10**, wherein the antibody is multispecific.

13. The antibody of claim **10**, wherein the antibody is bispecific.

14. A dimer comprising the polypeptide of claim **1**.

15. A heterodimer comprising the polypeptide of claim **1**.

16. A pharmaceutical composition comprising the polypeptide of claim **1** and a pharmaceutically acceptable carrier.

17. A pharmaceutical composition comprising the antibody of claim **10** and a pharmaceutically acceptable carrier.

18. An isolated nucleotide sequence encoding the polypeptide of claim **1**.

19. A vector comprising the nucleotide sequence of claim **18**.

20. A host cell comprising the vector of claim **19**.

21. A method of producing a polypeptide, comprising culturing the host cell of claim **20**, and producing the polypeptide.

* * * * *